





## How does Control-IQ technology work?

Control-IQ technology is designed to help increase time in range (70–180 mg/dL)* using Dexcom G6 continuous glucose monitoring (CGM) values to predict glucose levels 30 minutes ahead and adjust insulin delivery accordingly, including delivery of automatic correction boluses (up to one per hour).			Sleep Activity	Service Activity
<b>♦ Delivers</b>	Delivers an automatic correction bolus if sensor glucose is predicted to be above mg/dL	180		180
♦ B Increases	Increases basal insulin delivery if sensor glucose is predicted to be above mg/dL	160	120	160
♠ B Maintains	Maintains active Personal Profile settings when sensor glucose is between mg/dL	112.5 - 160	112.5 - 120	140 - 160
♦ B Decreases	Decreases basal insulin delivery if sensor glucose is predicted to be below mg/dL	112.5	112.5	140
	Stops basal insulin delivery if sensor glucose is predicted to be below mg/dL	70	70	80

## Control-IQ technology pump icons

lcon	Explanation		Icon	Explanation
<b>♦</b>	Control-IQ technology is on but not actively increasing or decreasing basal insulin delivery.		В	Control-IQ technology is delivering the normal Personal Profile basal rate.
<b>♦</b>	Control-IQ technology is increasing basal insulin delivery.		В	Control-IQ technology is increasing basal insulin delivery.
<b>�</b>	Control-IQ technology is decreasing basal insulin delivery.		В	Control-IQ technology is decreasing basal insulin delivery.
<b>♦</b>	Control-IQ technology has stopped basal insulin delivery.		0	Basal insulin delivery is stopped and a basal rate of 0 u/hr is active.
BOLUS ◆ ◆ ◆ Control·IQ: 2.8 u	Control-IQ technology is delivering an automatic correction bolus (or an automatic bolus).		•	Control-IQ technology is delivering an automatic correction bolus.
and the second	The Sleep Activity is enabled.	I	李	The Exercise Activity is enabled.

## Responsible Use of Control-IQ Technology

Even with advanced systems such as the t:slim X2 insulin pump with Control-IQ technology, you are still responsible for actively managing your diabetes. Control-IQ technology does not prevent all high and low blood glucose events. The system is designed to help reduce glucose variability, but it requires your accurate input of information, such as meals and periods of sleep or exercise. Control-IQ technology will not function as intended unless all system components, including CGM, infusion sets and pump cartridges, are used as instructed. Importantly, the system cannot adjust insulin dosing if the pump is not receiving CGM readings. Since there are situations and emergencies that the system may not be capable of identifying or addressing, patients should always pay attention to your symptoms and treat according to your healthcare provider's recommendations.

<sup>\*</sup> As measured by CGM. † If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL and delivers 60% of that value. An Automatic Correction Bolus will not occur within 60 minutes of a bolus that has been delivered or cancelled.

## Turn Control-IQ technology on or off



From the **Options** menu, tap **My Pump**.



Tap Control-IQ.



From this screen, Control-IQ technology can be toggled on or off.



Next, enter the user's weight in pounds and average daily insulin use in units.

► Note: Total Daily Insulin should be an estimate of total basal and bolus insulin the user requires in a 24-hour period.

Note: Existing t:slim X2 users can find their average Total Daily Insulin under Options, History, Pump History, Delivery Summary, and then 14-day Average.



Tap to save the settings. Control-IQ technology is now on.

Note: Patient must enter their weight, Total Daily Insulin (TDI), have an active Personal Profile with CARBS turned on, and an active CGM session, in order to turn Control-IQ technology on.

Important Safety Information: RX ONLY. The t:slim X2 pump and Control-IQ technology are intended for single patient use. The t:slim X2 pump and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The t:slim X2 pump is indicated for use in individuals six years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons six years of age and greater

WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds

Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using hydroxyurea. Users of the t:slim X2 pump and Control-IQ technology must: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump, and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

© 2022 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Control-IQ, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries. ML-1004929\_D